晚期NSCLC组织RRM1表达与化疗疗效相关性分析

Analysis of RRM1expression in advanced NSCLC and its relationship with chemotherapy

目的探索RRM1在非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中的表达及其对化疗疗效和预后的关系。方法 2010-01-31-2012-01-31海南省人民医院肿瘤内科收治晚期NSCLC患者138例,采用免疫组化SP法检测NSCLC患者组织RRM1表达情况,利用随机数字表将138例患者分为GP组72例(吉西他滨与顺铂联合化疗方案)与TP组66例(紫杉醇与顺铂联合化疗方案),观察其表达情况与化疗疗效与生存期的关系。结果 RRM1的表达与性别、年龄、肿瘤大小、病理类型、组织学分级及TNM分期均无相关性,P>0.05。66例TP组患者中,RRM1蛋白阳性表达有效率为50.00%(13/26),中位生存期9.1个月,1年生存率为42.31%(11/26),3年生存率为19.23%(5/26),阴性表达者有效率为52.50%(21/40),中位生存期11.6个月,1年生存率为40.00%(16/40),3年生存率为20.00%(8/40),两组比较差异无统计学意义,P>0.05;72例GP组患者中,RRM1蛋白阳性表达有效率为21.87%(7/32),中位生存期5.61个月,1年生存率为25.00%(8/32),3年生存率为12.50%(4/32);阴性表达有效率为40.00%(16/40),中位生存期13.32个月,1年生存率为42.50%(17/40),3年生存率为30.00%(12/40),两组比较差异有统计学意义,P<0.01。RRM1蛋白阳性组与RRM1阴性组的不良反应发生率差异无统计学意义,P>0.05。结论 RRM1的表达水平与吉西他滨化疗疗效及生存期呈负相关性,可为个体化疗提供依据。

OBJECTIVE To observe RRM1 expression in advanced NSCLC and its relationship with chemotherapy and prognosis. METHODS Immunohistochemistry was used to detect the expression of SP in 138 cases of RRM1 tissue of advanced non-small cell lung cancer patients. Coin toss was used to divide the patients into the GP group and the TP group. The relationships between the expression of chemotherapy and survival were observed. RESULTS RRM1 ex pression and gender, age, tumor size, histological type, histological grade and TNM stage showed no correlation, the difference was not statistically significant （P〈0.05）. In the 66 patients of the TP group, RRM1 protein positive expression was 50.00 % （13/26）, the median survival was 9.1 months, 1 year survival rate was 42.31%（17/40）, 3 year survival rate was 19.23 % （5/26）, the negative expression of effective rate was 52.50 % （21/40）. The median survival was 11.6 months, 1 year survival rate was 40.00%（16/40）, 3 year survival rate was 20.00%（8/40）, comparing the two groups there was no statistical significance, P〈0.05. In the 72 patients of GP group, RRM1 protein positive expression rate was 21.87%（7/32） with the median survival of 5.61 months, 1 year survival rate was 25.00% （8/32）, 3 year survival rate was 12. 50%（4/32）, the negative expression rate was 40.00%（16/40） with the median survival of 13.3 months, 1 year survival rate was 40.50% （17/40）, 3 year survival rate was 30.00%, comparing the two groups there was a statistical significance, P〈0.01. The difference of the incidence of adverse reactions in the RRM1 protein positive group and RRM1 negative group was no statistical significance （P〈0.05）. CONCLUSION RRM1 expression levels is negatively correla- ted with gemcitabine chemotherapy and survival, which can provide a basis as individuals chemotherapy.